ERBB2 and non-small cell lung carcinoma: In a phase II basket trial, patients with HER2-mutant NSCLC treated with T-DM1 had a median PFS of 5 months94, and a clinical benefit (ORR 44%) was subsequently confirmed in an exploratory phase II trial95.